Professor David Nutt (UK)
BA, MB BChir, MRCP, MA, DM, MRCPsych, FRCPsych, FMedSci, FRCP, FSB
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
Dr Rick Doblin (USA)
Dr Ben Sessa trained at UCL, London, graduating in Medicine in 1997.
He works clinically as an adult and adolescent psychiatrist, and academically in Bristol and Imperial College London University, with an interest in the developmental trajectory from child maltreatment to adult mental health disorders.
In the last ten years Ben has been a study doctor and a test subject administering and receiving legal doses of pure LSD, psilocybin, MDMA, DMT and Ketamine.
He is currently conducting the world’s first clinical study using MDMA to treat addiction. Ben is the co-founder and past President of the UK’s premier psychedelic research conference, Breaking Convention.
He has published dozens of peer reviewed papers on psychedelics and is the Author of several textbooks, including the influential book ‘The Psychedelic Renaissance’.
Dr Roland Griffiths (USA)
BSc, BA, Ph.D
Roland Griffiths, Ph.D., is Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. His principal research focus in both clinical and pre-clinical laboratories has been on the behavioural and subjective effects of mood-altering drugs. His research has been largely supported by grants from the National Institute on Health and he is author of 380 journal articles and book chapters. He has been a consultant to the National Institutes of Health, to numerous pharmaceutical companies in the development of new psychotropic drugs, and as a member of the Expert Advisory Panel on Drug Dependence for the World Health Organization. He has conducted extensive research with sedative-hypnotics, caffeine, and novel mood-altering drugs. In 1999 he initiated a research program investigating the effects of the classic psychedelic psilocybin that includes studies in psychedelic naive and experienced volunteers, in beginning and long-term meditators, and in religious leaders. Studies have also have examined the effects of salvinorin A, dextromethorphan, and ketamine which produce altered states of consciousness having some similarities to psilocybin. Therapeutic studies with psilocybin include treatment of psychological distress in cancer patients, treatment of cigarette smoking cessation, and psilocybin treatment of major depression. Drug interaction studies and brain imaging studies (fMRI and PET) are examining pharmacological and neural mechanisms of action. The Hopkins laboratory has also conducted a series of internet survey studies characterizing various psychedelic experiences including those associated with acute and enduring adverse effects, mystical-type effects, entity and God-encounter experiences, and alleged positive changes in mental health, including decreases in depression and anxiety, decreases in substance abuse, and reductions in death anxiety.